NASDAQ$DH
Definitive Healthcare Corp · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Definitive Healthcare's financial performance remained strong, marked by substantial revenue growth and strategic customer acquisitions.
Definitive Healthcare reported a 36% year-over-year increase in revenue, reaching $50.1 million for the first quarter of 2022. The company continued to grow its enterprise client base and achieved significant customer wins while also focusing on product innovation with the launch of the Passport Analytics Suite and Latitude Discovery.
- Revenue increased by 36% year-over-year, totaling $50.1 million compared to $36.9 million in Q1 2021.
- Net loss was ($13.1) million, representing 26% of revenue, compared to ($10.5) million, or 28% of revenue in Q1 2021.
- Adjusted EBITDA reached $14.0 million, accounting for 28% of revenue, slightly down from $14.1 million, or 38% of revenue in Q1 2021.
- The company ended the quarter with 447 enterprise customers, defined as those with more than $100,000 in annual recurring revenue.
Headline financials
Revenue & EPS history
Definitive Healthcare · Revenue · Quarterly
$50.1M
Forward guidance
Definitive Healthcare provided revenue guidance for Q2 2022 to be in the range of $53.0 - $54.0 million, a 34% increase year over year. Adjusted Operating Income is expected to be in the range of $13.0 – $14.0 million.
Tailwinds
- Revenue is expected to be in the range of $53.0 – $54.0 million, a 34% increase year over year.
- Adjusted Operating Income is expected to be in the range of $13.0 – $14.0 million.
- Adjusted EBITDA is expected to be in the range of $14.0 – $15.0 million.
- Adjusted Net Income is expected to be $7.0 – $8.0 million.
- Adjusted Net Income Per Diluted Share is expected to be $0.04 – $0.05 on approximately 154.8 million weighted-average shares outstanding.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2022
-3.2%
Avg return
Earnings day
-5.7%
Avg return
5 days after
-5.8%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+31.7%
Q1 2025
Best reaction
-34.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -2.0% | -5.2% | |
| Q4 2025 | -8.6% | -12.9% | -25.0% | |
| Q3 2025 | +11.9% | +2.6% | -6.4% | |
| Q1 2025 | +31.7% | +21.4% | +33.1% | |
| Q4 2024 | -34.3% | -43.7% | -40.2% | |
| Q3 2024 | -1.4% | +6.3% | +8.4% | |
| Q2 2024 | -1.4% | +5.1% | +21.6% | |
| Q1 2024 | -27.1% | -27.5% | -22.9% | |
| Q4 2023 | +2.3% | -4.2% | -13.3% | |
| Q3 2023 | +27.5% | +29.5% | +49.5% | |
| Q2 2023 | -4.0% | -6.2% | -21.2% | |
| Q1 2023 | +0.9% | -3.7% | +7.9% | |
| Q4 2022 | +3.5% | -1.6% | -11.5% | |
| Q3 2022 | -25.0% | -29.7% | -14.5% | |
| Q2 2022 | -16.3% | -18.6% | -35.7% | |
| Q1 2022 | -17.5% | -31.3% | -19.4% | |
| Q4 2021 | +7.6% | +13.6% | +14.0% | |
| Q3 2021 | -5.8% | +0.2% | -23.3% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro